WARMINSTER, Pa., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different mechanisms of action to provide a cure for people with chronic hepatitis B virus (HBV) infection and to treat coronaviruses (including COVID-19), today announced that the Company will be presenting data on the effects of its GalNAc-siRNA, AB-729, in chronic hepatitis B patients on nucleos(t)ide analogue therapy at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2021 – The Digital Experience™, taking place from November 12-15, 2021.
Poster Presentation Details:
Title: Low HBsAg levels maintained following cessation of the GalNAc-siRNA, AB-729, in chronic hepatitis B subjects on nucleos(t)ide analogue therapy
Publication Number: LP20
Session Title: Late-Breaking Abstract Posters
Authors: MF Yuen, E Berliba, W Sukeepaisarnjaroen, P Tangkijvanich, A Leerapun, J Holmes, E Gane, A Jucov, EP Thi, M Sofia, H Sevinsky, T Eley, E Medvedeva, K Gray, D Antoniello, G Picchio, KD Sims, SI Strasser
Poster Session Schedule:
Friday, November 12 - 1:00 PM – 3:00 PM ET Saturday, November 13 - 8:00 AM – 9:00 AM ET Sunday, November 14 - 8:00 AM – 9:00 AM ET Monday, November 15 - 2:00 PM – 3:00 PM ET
The poster will be available at the start of the The Liver Meeting® on November 12, 2021.
Key Findings:
- AB-729 repeat dosing is generally safe and well tolerated.
- Robust mean declines in HBsAg were sustained with repeat dosing of AB-729, with no meaningful differences observed to date between doses (60 mg or 90 mg) and/or dosing intervals (every 4, 8 or 12 weeks).
- HBsAg suppression at levels